Your session is about to expire
← Back to Search
Tegavivint for Recurrent or Refractory Cancer
Study Summary
This trial is testing a new drug to see if it can stop the growth of cancer cells.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have a tumor that cannot be removed by surgery or is dangerous, and it can be measured.I do not have a known metabolic bone disease.I do not have brain metastasis, except for craniopharyngeal tumors.I have a tumor that cannot be removed by surgery or is serious enough to consider treatment.I am not taking medication to prevent graft-versus-host disease after a bone marrow transplant.I have had a stem cell infusion, with or without full-body radiation.I do not have any infections that are not under control.I have a solid tumor, non-Hodgkin lymphoma, or desmoid tumor that has not responded to treatment.My kidney function is good based on recent tests.I am between 12 and 21 years old.I am not pregnant or breastfeeding and will use two forms of birth control during the study.I have a confirmed diagnosis of a solid tumor, non-Hodgkin lymphoma, or desmoid tumor that has come back or did not respond to treatment.I have a specific type of cancer or genetic mutation listed for PART B.My bilirubin levels are within the normal range for my age.My calcium levels are normal or can be corrected with oral supplements.I have recovered from previous cancer treatments and meet the required health criteria.I do not have a condition that affects how my bones process minerals.Your SGPT (ALT) level in your blood should be no higher than 135 U/L, with the normal upper limit being 45 U/L.Your albumin level in your blood is at least 2 g/dL within the last 7 days before joining the study.I have been on a stable or decreasing dose of corticosteroids for at least 7 days.I can join the study if my blood counts are okay, even with bone marrow cancer.I will take vitamin D (and calcium if needed) supplements if my levels are low.I do not have severe osteoporosis.I am between 12 months and 30 years old.I have not taken bisphosphonates in the last 4 weeks.I have not taken denosumab in the last 6 months.I do not have a primary brain tumor.I can take care of myself but might not be able to do active work.I am not taking any strong medication that affects enzyme CYP3A4.
- Group 1: Treatment (tegavivint)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this trial taking place in more than one state?
"There are a number of hospitals participating in this trial, 20 in total. Some notable locations include Children's Hospital Colorado in Aurora, UCSF Medical Center-Mission Bay in San Francisco, and Children's Hospital of Alabama in Birmingham."
For this particular test, are older individuals welcome to participate?
"According to the eligibility requirements, patients who wish to participate in this trial must be between 12 months and 30 years old. Out of the 11,076 total clinical trials taking place, 1,089 are for people under 18 while 9,187 are for those over 65."
How many candidates will be allowed to enroll in the research?
"In order for this research to be conducted, 147 individuals that fit the pre-determined inclusion criteria must participate. These potential participants can be found at Children's Hospital Colorado in Aurora, Colorado and UCSF Medical Center-Mission Bay in San Francisco, California among other locations."
Which type of person is this research looking for?
"This clinical trial is looking for 147 individuals that have been diagnosed with wilms tumor. The patients must be between 12 months and 30 years old, though there are different age requirements depending on which part of the study they hope to enroll in. Furthermore, candidates should meet one or more of the following criteria: having relapsed or refractory solid tumors (including non-Hodgkin lymphoma and desmoid tumors), being12 months to 21 years old at time of enrollment (for PART A), being recurrent or refractory Ewing sarcoma, desmoid tumors, osteosarcoma, liver tumors ("
Are people still being accepted into the trial program?
"According to the information displayed on clinicaltrials.gov, this trial is still looking for participants. The study was first advertised on October 25th 2021 and was last updated September 22nd 2022. So far, 147 patients have been recruited from 20 different centres."
Share this study with friends
Copy Link
Messenger